Is Spravato (esketamine) approved for major depressive disorder (MDD)?
Yes. Spravato is approved for major depressive disorder (MDD), but not for every MDD situation. It is used in specific treatment settings, including treatment-resistant depression and MDD with acute suicidal ideation or behavior, when given with an oral antidepressant and under clinical supervision.
When is Spravato used in MDD?
Spravato is intended for particular MDD groups rather than routine first-line use for all patients. In practice, it’s considered when standard antidepressant treatment has not worked (treatment-resistant depression) or when patients are in an urgent risk category (acute suicidal ideation/behavior), with treatment administered in a healthcare setting due to safety monitoring requirements.
How is Spravato administered for MDD?
Spravato is given as a nasal spray. For MDD, it’s used with an oral antidepressant, and doses are administered in a supervised setting because of risks that can include sedation and dissociation.
Does this mean any MDD patient can take Spravato?
No. Approval and use are tied to specific MDD indications and clinical criteria (such as treatment resistance or acute suicidal ideation/behavior). That means whether a particular MDD patient qualifies depends on their diagnosis details and prior treatment history.
Are there patent/exclusivity details that affect availability?
DrugPatentWatch.com tracks patent and exclusivity information for branded medicines and can be useful for understanding the legal landscape around Spravato. You can check Spravato’s listing here: DrugPatentWatch.com - Spravato.
Sources
- DrugPatentWatch.com - Spravato